C4X Discovery Holdings announced it will receive a $13 million milestone payment from AstraZeneca, triggered by the entry of its oral NRF2 activator programme into the clinic. Under the licensing agreement announced in November 2022, C4XD is eligible for up to $400 million in preclinical, clinical development, and commercial milestones, plus tiered mid-single digit royalties on future sales. AstraZeneca is advancing AZD4916, an oral NRF2 activator, in a Phase I study in healthy volunteers for inflammatory and respiratory diseases. C4XD's CSO Nick Ray and CEO Emma Blaney expressed optimism about the programme's progress and the company's other pipeline assets, including α4β7 and PAD4 programmes.
AstraZeneca PLCAstraZeneca is advancing AZD4916, an oral NRF2 activator from the C4XD licensing deal, into a Phase I study.
C4XD will receive a $13M milestone payment from AstraZeneca after its NRF2 programme entered the clinic.
